相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas
Zhi-hua Ye et al.
ONCOTARGETS AND THERAPY (2017)
Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia
Alyssa Carey et al.
CELL REPORTS (2017)
Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial
Ruben A. Mesa et al.
LANCET HAEMATOLOGY (2017)
Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia
Kaiwei Liang et al.
CELL (2017)
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells
Bin Zhang et al.
BLOOD (2016)
FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Elie Traer et al.
CANCER RESEARCH (2016)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji et al.
BLOOD (2015)
Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells
Robert S. Welner et al.
CANCER CELL (2015)
Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies
Zhaoyang Li et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Targeting IRAK1 in T-Cell acute lymphoblastic leukemia
Charles Dussiau et al.
ONCOTARGET (2015)
PhosphoSitePlus, 2014: mutations, PTMs and recalibrations
Peter V. Hornbeck et al.
NUCLEIC ACIDS RESEARCH (2015)
BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein
Anupriya Agarwal et al.
BLOOD (2014)
Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma
Dongmei Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
IRAK1: oncotarget in MDS and AML
Levi J. Beverly et al.
ONCOTARGET (2014)
IL-1 receptor-associated kinase signaling and its role in inflammation, cancer progression, and therapy resistance
Ajay Jain et al.
FRONTIERS IN IMMUNOLOGY (2014)
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia
Guang Yang et al.
BLOOD (2013)
Outcome of older patients with acute myeloid leukemia: An Analysis of SEER Data Over 3 Decades
Mya S. Thein et al.
CANCER (2013)
Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome
Garrett W. Rhyasen et al.
CANCER CELL (2013)
Differential IRAK signaling in hematologic malignancies
Garrett W. Rhyasen et al.
EXPERIMENTAL HEMATOLOGY (2013)
Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Status
Jorge E. Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia
C. Jimenez et al.
LEUKEMIA (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS
Laura Barreyro et al.
BLOOD (2012)
Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)
Anders Poulsen et al.
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN (2012)
FLT3-Mediated p38-MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis
Christophe Desterke et al.
CANCER RESEARCH (2011)
MicroRNA-146a disrupts hematopoietic differentiation and survival
Daniel T. Starczynowski et al.
EXPERIMENTAL HEMATOLOGY (2011)
Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes
Sigurdur Y. Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
Anthony D. William et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies
S. Hart et al.
LEUKEMIA (2011)
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo et al.
NATURE (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
S. Hart et al.
BLOOD CANCER JOURNAL (2011)
Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling
Su-Chang Lin et al.
NATURE (2010)
TLR8-dependent TNF-α overexpression in Fanconi anemia group C cells
Scott M. Vanderwerf et al.
BLOOD (2009)
Activation mechanisms of STAT5 by oncogenic Flt3-ITD
Chunaram Choudhary et al.
BLOOD (2007)
An iterative statistical approach to the identification of protein phosphorylation motifs from large-scale data sets
D Schwartz et al.
NATURE BIOTECHNOLOGY (2005)
Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-α induction
S Uematsu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The JAK/STAT signaling pathway
JS Rawlings et al.
JOURNAL OF CELL SCIENCE (2004)
分享论文
